Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation.

David Avigan(Beth Israel Deaconess Medical Center), Donald Küfe(Dana-Farber Cancer Institute), J Milano, L. Kennedy, Paul G. Richardson(Harvard University), Jianlin Gong(Harvard University), Anthony Elias(University of Colorado Cancer Center), Zhiyou Wu(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), J Levine, Kenneth C. Anderson(Dana-Farber Cancer Institute)
PubMed
October 1, 1999
Cited by 36

Related Papers

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k